Genenta Science (GNTA) Short Interest Ratio & Short Volume $3.76 -0.02 (-0.40%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Genenta Science Short Interest DataGenenta Science (GNTA) has a short interest of 3,900 shares, representing 0.03% of the float (the number of shares available for trading by the public). This marks a 39.29% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 17,022 shares to cover all short positions.Current Short Interest3,900 sharesPrevious Short Interest2,800 sharesChange Vs. Previous Month+39.29%Dollar Volume Sold Short$11.90 thousandShort Interest Ratio0.3 Days to CoverLast Record DateJune 30, 2025Outstanding Shares18,290,000 sharesShort Percent of Float0.03%Today's Trading Volume882 sharesAverage Trading Volume17,022 sharesToday's Volume Vs. Average5% Short Selling Genenta Science? Sign up to receive the latest short interest report for Genenta Science and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGNTA Short Interest Over TimeGNTA Days to Cover Over TimeGNTA Percentage of Float Shorted Over Time Genenta Science Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20253,900 shares $11.90 thousand +39.3%0.0%0.3 $3.05 6/15/20252,800 shares $10.85 thousand +40.0%0.0%0.5 $3.88 5/31/20252,000 shares $8.96 thousand -31.0%0.0%0.1 $4.48 5/15/20252,900 shares $12.21 thousand -17.1%0.0%0.2 $4.21 4/30/20253,500 shares $13.62 thousand +45.8%N/A0.2 $3.89 4/15/20252,400 shares $9.19 thousand +84.6%0.0%0.1 $3.83 3/31/20251,300 shares $5.06 thousand No Change0.0%0.1 $3.90 3/15/20251,300 shares $4.99 thousand -13.3%0.0%0.1 $3.84 2/28/20251,500 shares $5.85 thousand -40.0%0.0%0.1 $3.90 2/15/20252,500 shares $10.93 thousand -26.5%0.0%0.2 $4.37 Get the Latest News and Ratings for GNTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. 1/31/20253,400 shares $11.97 thousand +30.8%N/A0.3 $3.52 1/15/20252,600 shares $10.63 thousand +18.2%N/A0.2 $4.09 12/31/20242,200 shares $9.57 thousand -29.0%N/A0.1 $4.35 12/15/20243,100 shares $15.90 thousand +121.4%N/A0.2 $5.13 11/30/20241,400 shares $7.28 thousand -64.1%N/A0.1 $5.20 11/15/20243,900 shares $19.58 thousand -26.4%N/A0.3 $5.02 10/31/20245,300 shares $27.03 thousand -54.3%N/A0.4 $5.10 10/15/202411,600 shares $67.28 thousand +152.2%N/A0.9 $5.80 9/30/20244,600 shares $19.64 thousand -20.7%N/A0.3 $4.27 9/15/20245,800 shares $22.91 thousand -40.8%N/A0.5 $3.95 8/31/20249,800 shares $37.93 thousand -18.3%N/A0.8 $3.87 8/15/202412,000 shares $52.20 thousand -14.9%N/A1.1 $4.35 7/31/202414,100 shares $60.63 thousand +227.9%N/A1.2 $4.30 7/15/20244,300 shares $14.88 thousand +4.9%N/A0.3 $3.46 6/30/20244,100 shares $12.71 thousand -18.0%N/A1 $3.10 6/15/20245,000 shares $16.19 thousand +47.1%N/A1.2 $3.24 5/31/20243,400 shares $11.66 thousand +79.0%N/A0.6 $3.43 5/15/20241,900 shares $6.08 thousand -60.4%N/A0.3 $3.20 4/30/20244,800 shares $14.78 thousand +23.1%N/A0.8 $3.08 4/15/20243,900 shares $13.12 thousand +30.0%N/A0.7 $3.37 3/31/20243,000 shares $10.50 thousand -9.1%N/A0.7 $3.50 3/15/20243,300 shares $12.87 thousand -5.7%N/A0.8 $3.90 2/29/20243,500 shares $15.40 thousand -5.4%N/A1.2 $4.40 2/15/20243,700 shares $14.80 thousand +5.7%N/A1.3 $4.00 1/31/20243,500 shares $14.11 thousand -5.4%N/A1.3 $4.03 1/15/20243,700 shares $16.47 thousand No ChangeN/A1.8 $4.45 12/31/20233,700 shares $18.32 thousand -32.7%N/A1.7 $4.95 12/15/20235,500 shares $27.61 thousand +14.6%N/A2.5 $5.02 11/30/20234,800 shares $23.76 thousand -35.1%N/A2.4 $4.95 11/15/20237,400 shares $38.48 thousand +37.0%N/A3.9 $5.20Your Bank Account Is No Longer Safe (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 10/31/20235,400 shares $28.84 thousand -25.0%N/A3.2 $5.34 10/15/20237,200 shares $40.25 thousand +1.4%N/A3.8 $5.59 9/30/20237,100 shares $36.57 thousand +10.9%N/A4.4 $5.15 9/15/20236,400 shares $36.03 thousand -1.5%N/A3.6 $5.63 8/31/20236,500 shares $37.70 thousand -17.7%N/A3.2 $5.80 8/15/20237,900 shares $43.69 thousand +9.7%N/A3.4 $5.53 7/31/20237,200 shares $39.17 thousand +50.0%N/A3 $5.44 7/15/20234,800 shares $28.56 thousand -14.3%N/A2.2 $5.95 6/30/20235,600 shares $32.98 thousand +7.7%N/A2.7 $5.89 6/15/20235,200 shares $29.85 thousand +300.0%N/A2.4 $5.74 5/31/20231,300 shares $7.93 thousand -23.5%N/A0.5 $6.10 5/15/20231,700 shares $9.54 thousand +54.6%N/A0.7 $5.61 4/30/20231,100 shares $6.60 thousand +266.7%N/A0.4 $6.00 4/15/2023300 shares $1.89 thousand No ChangeN/A0.1 $6.30 3/31/2023300 shares $1.73 thousand -40.0%N/A0.1 $5.75 3/15/2023500 shares $3.35 thousand -66.7%N/A0.1 $6.70 2/28/20231,500 shares $9.75 thousand +114.3%N/A0.3 $6.50 2/15/2023700 shares $4.59 thousand -22.2%N/A0.2 $6.55 1/31/2023900 shares $5.53 thousand -50.0%N/A0.2 $6.14 1/15/20231,800 shares $11.61 thousand -30.8%N/A0.4 $6.45 12/30/20222,600 shares $14.30 thousand +116.7%N/A0.6 $5.50 12/15/20221,200 shares $6.78 thousand +140.0%N/A0.4 $5.65 11/30/2022500 shares $2.61 thousand -80.8%N/A0.2 $5.21 11/15/20222,600 shares $10.82 thousand +225.0%N/A1.2 $4.16 10/31/2022800 shares $3.52 thousand +33.3%N/A0.4 $4.40 10/15/2022600 shares $2.74 thousand -25.0%N/A0.3 $4.57 9/30/2022800 shares $3.98 thousand -11.1%N/A0.3 $4.98 9/15/2022900 shares $4.72 thousand +125.0%N/A0.3 $5.24 8/31/2022400 shares $2.37 thousand -71.4%N/A0.1 $5.92 8/15/20221,400 shares $8.88 thousand -12.5%N/A0.4 $6.34 7/31/20221,600 shares $10.51 thousand -46.7%N/A0.3 $6.57 7/15/20223,000 shares $20.22 thousand No ChangeN/A0.6 $6.74 GNTA Short Interest - Frequently Asked Questions What is Genenta Science's current short interest? Short interest is the volume of Genenta Science shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 3,900 shares of GNTA short. 0.03% of Genenta Science's shares are currently sold short. Learn More on Genenta Science's current short interest. What is a good short interest percentage for Genenta Science? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Genenta Science's floating shares are currently sold short. Is Genenta Science's short interest increasing or decreasing? Genenta Science saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,900 shares, an increase of 39.3% from the previous total of 2,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Genenta Science's short interest compare to its competitors? 0.03% of Genenta Science's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Genenta Science: Entrada Therapeutics, Inc. (5.60%), Corvus Pharmaceuticals, Inc. (18.26%), 2seventy bio, Inc. (5.37%), Tonix Pharmaceuticals Holding Corp. (16.46%), Allogene Therapeutics, Inc. (13.99%), Inozyme Pharma, Inc. (7.79%), Aldeyra Therapeutics, Inc. (8.26%), Candel Therapeutics, Inc. (17.93%), Aurora Cannabis Inc. (12.25%), Sagimet Biosciences Inc. (15.27%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Genenta Science stock? Short selling GNTA is an investing strategy that aims to generate trading profit from Genenta Science as its price is falling. GNTA shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Genenta Science? A short squeeze for Genenta Science occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GNTA, which in turn drives the price of the stock up even further. How often is Genenta Science's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNTA, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Entrada Therapeutics Short Squeeze Corvus Pharmaceuticals Short Squeeze 2seventy bio Short Squeeze Tonix Pharmaceuticals Short Squeeze Allogene Therapeutics Short Squeeze Inozyme Pharma Short Squeeze Aldeyra Therapeutics Short Squeeze Candel Therapeutics Short Squeeze Aurora Cannabis Short Squeeze Sagimet Biosciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GNTA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.